of unsupported charges as a condition of release despite no contractual obligation, withholding shipping documentation, and other acts or omissions of Respondents.

Pursuant to the order issued by the presiding judge on June 30, 2026, titled ''Order Denying Respondent Freightlead LLC's Motion to Dismiss Without Prejudice and Directing Complaint to File Amended Complaint,'' answers to the amended complaint must be filed with the Commission no later than July 28, 2026.

The full text of the amended complaint can be found in the Commission's electronic Reading Room at *https://www2.fmc.gov/readingroom/proceeding/26-02/*.

This proceeding has been assigned to the Office of Administrative Law Judges. The initial decision of the presiding judge shall be issued by January 14, 2027, and the final decision of the Commission shall be issued by July 28, 2027.

(Authority: 46 U.S.C. 41301; 46 CFR 502.61(c).)

Served: July 15, 2026.

David Eng,

Secretary.

[FR Doc. 2026–14541 Filed 7–17–26; 8:45 am]

BILLING CODE 6730–02–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Medicare & Medicaid Services

[CMS–4219–N]

Medicare Program; Inflation Reduction Act of 2022 (IRA) Medicare Drug Price Negotiation Program Draft Guidance; Comment Request

AGENCY: Centers for Medicare & Medicaid Services (CMS), Department of Health and Human Services (HHS).

ACTION: Notice.

SUMMARY: The Centers for Medicare & Medicaid Services (CMS) is announcing an opportunity for the public to comment on CMS' draft guidance for the Medicare Drug Price Negotiation Program regarding manufacturer effectuation of the maximum fair price in 2028 for the implementation of the Inflation Reduction Act of 2022 (IRA) (Pub. L. 117–169). CMS' draft guidance and other IRA-related guidance can be viewed on the CMS website at *https://www.cms.gov/priorities/medicare-prescription-drug-affordability/medicare-prescription-drug-affordability.*

DATES: Comments must be received by September 18, 2026.

ADDRESSES: Written comments should be sent to *IRARebateandNegotiation@cms.hhs.gov* with the subject line, ''Medicare Drug Price Negotiation Program Draft Guidance''.

FOR FURTHER INFORMATION CONTACT: Elisabeth Daniel, *IRARebateandNegotiationprogram@cms.hhs.gov,* or (667) 290–8793.

SUPPLEMENTARY INFORMATION: The Inflation Reduction Act of 2022 (IRA) was signed into law on August 16, 2022. Sections 11001 and 11002 of the IRA established the Medicare Drug Price Negotiation Program (hereafter the ''Negotiation Program'') to negotiate maximum fair prices (MFPs) for certain high expenditure, single source drugs and biological products. The requirements for this program are described in sections 1191 through 1198 of the Social Security Act as added by sections 11001 and 11002 of the IRA. The draft guidance specifies the requirements for manufacturer effectuation of the MFPs in 2028.

To obtain copies of the draft guidance and other IRA-related documents, please access the CMS website by copying and pasting the following web address into your web browser: *https://www.cms.gov/inflation-reduction-act-and-medicare.* If interested in receiving CMS Inflation Reduction Act updates by email, individuals may sign up for CMS' IRA email updates at *https://www.cms.gov/priorities/medicare-prescription-drug-affordability/medicare-prescription-drug-affordability.*

The Administrator of the Centers for Medicare & Medicaid Services (CMS), Dr. Mehmet Oz, having reviewed and approved this document, authorizes Chyana Woodyard, who is the Federal Register Liaison, to electronically sign this document for purposes of publication in the **Federal Register**.

Chyana Woodyard,

Federal Register Liaison, Centers for Medicare & Medicaid Services.

[FR Doc. 2026–14583 Filed 7–16–26; 4:15 pm]

BILLING CODE 4169–69–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

Privacy Act of 1974; System of Records

AGENCY: Office of Family Assistance (OFA), Administration for Children and Families (ACF), Department of Health and Human Services (HHS).

ACTION: Extension of comment period for and the effective date of the new routine use under modified system of records.

SUMMARY: The Department of Health and Human Services (HHS) is extending the comment period for and the effective date of the new routine use under the modified system of records maintained by the Office of Family Assistance (OFA) within HHS' Administration for Children and Families (ACF), System No. 09–80–0375, Temporary Assistance for Needy Families (TANF) Data that appeared in the **Federal Register** of June 23, 2026. We are taking this action in response to an issue that prevented the public from commenting through the Federal eRulemaking Portal until July 10, 2026.

DATES: ACF is extending the comment period for and the effective date of the new routine use under the modified system of records published June 23, 2026 (91 FR 37406). In accordance with 5 U.S.C. 552a(e)(4) and (11), the notice was effective June 23, 2026, with the exception of subparagraph a under routine use 1 and the new routine use 10, which will be effective August 11, 2026. Please submit any comments on the notice by August 11, 2026.

ADDRESSES: Comments may be submitted to the Federal eRulemaking Portal electronically at *http://www.regulations.gov* or mailed to John Talieri, Senior Official for Privacy, Administration for Children and Families, 330 C Street SW, Washington DC 20201. Please include ''09–80–0375'' in the subject line or *regulations.gov* comment. Comments received will be available at *regulations.gov* for public viewing, inspection or copies. ACF does not edit personally identifiable information from submissions; therefore, commenters should submit only information that they wish to make publicly available.

FOR FURTHER INFORMATION CONTACT: General questions about the modified system of records may be submitted by mail or email to TANF Data Division, Office of Family Assistance, Administration for Children and Families, 330 C Street SW, Washington, DC 20201, or *tanfdata@acf.hhs.gov;* or may be submitted by telephone to John Talieri, Senior Official for Privacy, at (202) 969–3581.